Thank you Heskumdai - that is an excellent leading question. I...

Thank you Heskumdai - that is an excellent leading question. I have no doubt that Big Pharma are excited by the possibility of transporting approved drugs into cells through a peptide delivery system. The deal with Janssen is still under wraps but potentially could be expanded to $1B - concurrently Janssen (and possibly several other groups) are doing due diligence on taking up a strategic equity stake in Phylogica.

Its probably befuddling to shareholders to describe developments as exciting, given the weariness which comes from a depressed share price. Nonetheless, take on board the importance of the Chairman's statement;

"There is an enormous opportunity in pursuing these intracellular targets, which, if successfully drugged could lead to new treatment approaches to some of the world's major unmet medical needs such as neurodegenerative disorders, cancer and auto-immune diseases," said Wilson.

Big Pharma have the drugs - just possibly Phylogica can provide the mechanism to transport those drugs into cells.

Would it be a faster way to a commercial outcome if the peptide is carrying an approved drug? I can't answer Heskumdai's question but strongly sense that the answer may not be far away.